Literature DB >> 17691

The identification and analysis of mexiletine and its metabolic products in man.

A H Beckett, E C Chidomere.   

Abstract

Sensitive and specific gas-liquid chromatographic methods were developed for the analysis of mexiletine and its metabolites in urine of man. The identity of the g.l.c. peaks was established by mass-spectrometry. The hydroxylamine (Va) was qualitatively identified and determined quantitatively after conversion to the more stable oxime (Vb). Selective extraction procedures, t.l.c. and derivatization with hexamethyldisilazane (HMDS) and trifluoroacetic anhydride (TFA) were used in the qualitative identification of the major metabolites (VI-IX), particularly in distinguishing the basic products VI and VII from their corresponding alcoholic products VIII and IX. The limit of detection of the g.l.c. method was 6 to 12 ng ml-1 for compounds I-IV, and 40 to 50 ng ml-1 for compounds Vb-IX.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 17691     DOI: 10.1111/j.2042-7158.1977.tb11312.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  7 in total

Review 1.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

3.  Impact of CYP2D6*10 on mexiletine pharmacokinetics in healthy adult volunteers.

Authors:  Masahiro Otani; Tsuyoshi Fukuda; Masakazu Naohara; Hiromi Maune; Chiaki Senda; Isamu Yamamoto; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2003-08-23       Impact factor: 2.953

4.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 5.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

6.  Stereoselective disposition of mexiletine in man.

Authors:  O Grech-Belanger; J Turgeon; M Gilbert
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

7.  Evaluation of the pharmacological activity of the major mexiletine metabolites on skeletal muscle sodium currents.

Authors:  M De Bellis; A De Luca; F Rana; M M Cavalluzzi; A Catalano; G Lentini; C Franchini; V Tortorella; D Conte Camerino
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.